Patents by Inventor Ahmed Elkashef

Ahmed Elkashef has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treating conditions caused by higher-than-normal dopaminergic activity in basal ganglia
    Patent number: 8592466
    Abstract: Treatment of humans suffering from conditions caused by higher-than-normal dopaminergic activity in basal ganglia includes administering the compound (2S)-2-{3-[3-({[(2R,4R)-4-tert-Butoxycarbonyl-2-(2-fluorophenyl)]-3-thiazolidinyl}carbonylmethyl)ureido]phenyl}propionic acid and its physiological acceptable salts.
    Type: Grant
    Filed: July 18, 2012
    Date of Patent: November 26, 2013
    Assignee: Neuropill, Inc.
    Inventor: Ahmed Elkashef
  • Methods for Treating Conditions Caused by Higher-Than-Normal Dopaminergic Activity In Basal Ganglia
    Publication number: 20120289556
    Abstract: Treatment of humans suffering from conditions caused by higher-than-normal dopaminergic activity in basal ganglia includes administering the compound (2S)-2-{3-[3-({[(2R,4R)-4-tert-Butoxycarbonyl-2-(2-fluorophenyl)]-3-thiazolidinyl}carbonylmethyl)ureido]phenyl}propionic acid and its physiological acceptable salts.
    Type: Application
    Filed: July 18, 2012
    Publication date: November 15, 2012
    Applicant: Neuropill, Inc.
    Inventor: Ahmed ELKASHEF
  • Methods for treating schizophrenia
    Patent number: 8247438
    Abstract: Treatment of schizophrenia or humans suffering from conditions associated with high dopamine levels in ventral striatum or caudate nucleus administers the compound (2S)-2-{3-[3-({[(2R,4R)-4-tert-Butoxycarbonyl-2-(2-fluorophenyl)]-3-thiazolidinyl}carbonylmethyl)ureido]phenyl}propionic acid and its physiological acceptable salts.
    Type: Grant
    Filed: June 10, 2008
    Date of Patent: August 21, 2012
    Assignee: Neuropill, Inc.
    Inventor: Ahmed Elkashef
  • METHODS FOR TREATING SCHIZOPHRENIA
    Publication number: 20090215840
    Abstract: Treatment of schizophrenia or humans suffering from conditions associated with high dopamine levels in ventral striatum or caudate nucleus administers the compound (2S)-2-{3-[3-({[(2R,4R)-4-tert-Butoxycarbonyl-2-(2-fluorophenyl)]-3-thiazolidinyl}carbonylmethyl) ureido]phenyl} propionic acid and its physiological acceptable salts.
    Type: Application
    Filed: June 10, 2008
    Publication date: August 27, 2009
    Applicant: Neuropill, Inc
    Inventor: Ahmed Elkashef